Mechanism and clinical significance of YAP in the progression of gastric cancer

doi:10.3760/cma.j.cn371439-20220627-00135

Abstract

Abstract:

Gastric cancer is one of the common malignant tumors with a high incidence in China. With the deepening of the research on tumor molecular biology， molecular targeted therapy has shown its advantages， and immunotherapy has attracted much attention. Yes-associated protein （YAP） is an effector protein that plays a major role in Hippo pathway， and it can regulate the growth of cells after binding with transcription factors in the nucleus. In recent years， many studies have shown that the high expression of YAP is closely related to the occurrence， development and metastasis of gastric cancer， and may be an important target of chemotherapy resistance. The further study can provide reference for clinical treatment.

Key words: Gastric neoplasms, Yes-associated protein, Hippo pathway

Cai Jiahui, Rong Guanghong. Mechanism and clinical significance of YAP in the progression of gastric cancer[J]. Journal of International Oncology, 2022, 49(11): 687-691.

References 36

[1]	Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3): 264-279. DOI: 10.3322/caac.21657. doi: 10.3322/caac.21657
[2]	Puliga E, Corso S, Pietrantonio F, et al. Microsatellite instability in gastric cancer: between lights and shadows[J]. Cancer Treat Rev, 2021, 95: 102175. DOI: 10.1016/j.ctrv.2021.102175. doi: 10.1016/j.ctrv.2021.102175
[3]	Mohajan S, Jaiswal PK, Vatanmakarian M, et al. Hippo pathway: regulation, deregulation and potential therapeutic targets in cancer[J]. Cancer Lett, 2021, 507: 112-123. DOI: 10.1016/j.canlet.2021.03.006. doi: 10.1016/j.canlet.2021.03.006 pmid: 33737002
[4]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492
[5]	Masliantsev K, Karayan-Tapon L, Guichet PO. Hippo signaling pathway in gliomas[J]. Cells, 2021, 10(1): 184. DOI: 10.3390/cells10010184. doi: 10.3390/cells10010184
[6]	Seeneevassen L, Dubus P, Gronnier C, et al. Hippo in gastric cancer: from signalling to therapy[J]. Cancers (Basel), 2022, 14(9): 2282. DOI: 10.3390/cancers14092282. doi: 10.3390/cancers14092282
[7]	Han T, Cheng Z, Xu M, et al. Yes-associated protein contributes to cell proliferation and migration of gastric cancer via activation of Gli1[J]. Onco Targets Ther, 2020, 13: 10867-10876. DOI: 10.2147/OTT.S266449. doi: 10.2147/OTT.S266449
[8]	Bie Q, Li X, Liu S, et al. YAP promotes self-renewal of gastric cancer cells by inhibiting expression of L-PTGDS and PTGDR2[J]. Int J Clin Oncol, 2020, 25(12): 2055-2065. DOI: 10.1007/s10147-020-01771-1. doi: 10.1007/s10147-020-01771-1
[9]	Yuan W, Chen S, Li B, et al. The N⁶-methyladenosine reader protein YTHDC2 promotes gastric cancer progression via enhancing YAP mRNA translation[J]. Transl Oncol, 2022, 16: 101308. DOI: 10.1016/j.tranon.2021.101308. doi: 10.1016/j.tranon.2021.101308
[10]	Qiu T, Zhang D, Xu J, et al. Yes-associated protein gene over-expression regulated by β-catenin promotes gastric cancer cell tumo-rigenesis[J]. Technol Health Care, 2022, 30(S1): 425-440. DOI: 10.3233/THC-THC228039. doi: 10.3233/THC-THC228039
[11]	Yan H, Qiu C, Sun W, et al. Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy[J]. Oncol Rep, 2018, 39(4): 1671-1681. DOI: 10.3892/or.2018.6252. doi: 10.3892/or.2018.6252 pmid: 29436693
[12]	Liu H, Mei D, Xu P, et al. YAP promotes gastric cancer cell survival and migration/invasion via the ERK/endoplasmic reticulum stress pathway[J]. Oncol Lett, 2019, 18(6): 6752-6758. DOI: 10.3892/ol.2019.11049. doi: 10.3892/ol.2019.11049 pmid: 31807184
[13]	Jiang L, Wang W, Li Z, et al. NUPR1 participates in YAP-mediate gastric cancer malignancy and drug resistance via AKT and p21 activation[J]. J Pharm Pharmacol, 2021, 73(6): 740-748. DOI: 10.1093/jpp/rgab010. doi: 10.1093/jpp/rgab010 pmid: 33793788
[14]	Kim E, Ahn B, Oh H, et al. High Yes-associated protein 1 with concomitant negative LATS1/2 expression is associated with poor prognosis of advanced gastric cancer[J]. Pathology, 2019, 51(3): 261-267. DOI: 10.1016/j.pathol.2019.01.001. doi: 10.1016/j.pathol.2019.01.001
[15]	Wang H, Di X, Bi Y, et al. Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p[J]. Bioengineered, 2021, 12(1): 1791-1802. DOI: 10.1080/21655979.2021.1924554. doi: 10.1080/21655979.2021.1924554 pmid: 33975517
[16]	Molina-Castro SE, Tiffon C, Giraud J, et al. The hippo kinase LATS2 controls helicobacter pylori-induced epithelial-mesenchymal transition and intestinal metaplasia in gastric mucosa[J]. Cell Mol Gastroenterol Hepatol, 2020, 9(2): 257-276. DOI: 10.1016/j.jcmgh.2019.10.007. doi: S2352-345X(19)30143-2 pmid: 31669263
[17]	Giraud J, Molina-Castro S, Seeneevassen L, et al. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells[J]. Int J Cancer, 2020, 146(8): 2255-2267. DOI: 10.1002/ijc.32667. doi: 10.1002/ijc.32667 pmid: 31489619
[18]	Gao J, Zhang Y, Chen H, et al. Computational insights into the interaction mechanism of transcription cofactor vestigial-like protein 4 binding to TEA domain transcription factor 4 by molecular dynamics simulation and molecular mechanics generalized Born/surface area calculation[J]. J Biomol Struct Dyn, 2019, 37(10): 2538-2545. DOI: 10.1080/07391102.2018.1491889. doi: 10.1080/07391102.2018.1491889
[19]	Jiao S, Guan J, Chen M, et al. Targeting IRF3 as a YAP agonist therapy against gastric cancer[J]. J Exp Med, 2018, 215(2): 699-718. DOI: 10.1084/jem.20171116. doi: 10.1084/jem.20171116
[20]	Chuang LSH, Ito Y. The multiple interactions of RUNX with the Hippo-YAP pathway[J]. Cells, 2021, 10(11): 2925. DOI: 10.3390/cells10112925. doi: 10.3390/cells10112925
[21]	Tang Y, Fang G, Guo F, et al. Selective inhibition of STRN3-containing PP2A phosphatase restores hippo tumor-suppressor activity in gastric cancer[J]. Cancer Cell, 2020, 38(1): 115-128.e9. DOI: 10.1016/j.ccell.2020.05.019. doi: S1535-6108(20)30269-5 pmid: 32589942
[22]	Seeneevassen L, Giraud J, Molina-Castro S, et al. Leukaemia inhibitory factor (LIF) inhibits cancer stem cells tumorigenic pro-perties through hippo kinases activation in gastric cancer[J]. Cancers (Basel), 2020, 12(8): 2011. DOI: 10.3390/cancers12082011. doi: 10.3390/cancers12082011
[23]	Wang Q, Lu P, Wang T, et al. Sitagliptin affects gastric cancer cells proliferation by suppressing melanoma-associated antigen-A3 expression through Yes-associated protein inactivation[J]. Cancer Med, 2020, 9(11): 3816-3828. DOI: 10.1002/cam4.3024. doi: 10.1002/cam4.3024
[24]	Chen T, Zhao L, Chen S, et al. The curcumin analogue WZ35 affects glycolysis inhibition of gastric cancer cells through ROS-YAP-JNK pathway[J]. Food Chem Toxicol, 2020, 137: 111131. DOI: 10.1016/j.fct.2020.111131. doi: 10.1016/j.fct.2020.111131
[25]	Liu Q, Xia H, Zhou S, et al. Simvastatin inhibits the malignant behaviors of gastric cancer cells by simultaneously suppressing YAP and β-catenin signaling[J]. Onco Targets Ther, 2020, 13: 2057-2066. DOI: 10.2147/OTT.S237693. doi: 10.2147/OTT.S237693
[26]	Chao J, Fuchs CS, Shitara K, et al. Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy[J]. J Clin Oncol, 2020, 38(4_suppl): 430. DOI: 10.1200/JCO.2020.38.4_suppl.430. doi: 10.1200/JCO.2020.38.4_suppl.430
[27]	Fuchs CS, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial[J]. Gastric Cancer, 2022, 25(1): 197-206. DOI: 10.1007/s10120-021-01227-z. doi: 10.1007/s10120-021-01227-z
[28]	Hsu PC, Miao J, Wang YC, et al. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma[J]. J Cell Mol Med, 2018, 22(6): 3139-3148. DOI: 10.1111/jcmm.13593. doi: 10.1111/jcmm.13593
[29]	Yu M, Peng Z, Qin M, et al. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation[J]. Mol Cell, 2021, 81(6): 1216-1230.e9. DOI: 10.1016/j.molcel.2021.01.010. doi: 10.1016/j.molcel.2021.01.010 pmid: 33606996
[30]	Ge S, Xia X, Ding C, et al. A proteomic landscape of diffuse-type gastric cancer[J]. Nat Commun, 2018, 9(1): 1012. DOI: 10.1038/s41467-018-03121-2. doi: 10.1038/s41467-018-03121-2 pmid: 29520031
[31]	Guo X, Zhao Y, Yan H, et al. Single tumor-initiating cells evade immune clearance by recruiting type Ⅱ macrophages[J]. Genes Dev, 2017, 31(3): 247-259. DOI: 10.1101/gad.294348.116. doi: 10.1101/gad.294348.116
[32]	Zhang K, Li J, Shi Z, et al. Ginsenosides regulates innate immunity to affect immune microenvironment of AIH through Hippo-YAP/TAZ signaling pathway[J]. Front Immunol, 2022, 13: 851560. DOI: 10.3389/fimmu.2022.851560. doi: 10.3389/fimmu.2022.851560
[33]	Wang J, Huang F, Shi Y, et al. RP11-323N12.5 promotes the malignancy and immunosuppression of human gastric cancer by increasing YAP1 transcription[J]. Gastric Cancer, 2021, 24(1): 85-102. DOI: 10.1007/s10120-020-01099-9. doi: 10.1007/s10120-020-01099-9
[34]	Koo JH, Guan KL. Interplay between YAP/TAZ and metabolism[J]. Cell Metab, 2018, 28(2): 196-206. DOI: 10.1016/j.cmet.2018.07.010. doi: S1550-4131(18)30453-4 pmid: 30089241
[35]	Yong J, Li Y, Lin S, et al. Inhibitors targeting YAP in gastric cancer: current status and future perspectives[J]. Drug Des Devel Ther, 2021, 15: 2445-2456. DOI: 10.2147/DDDT.S308377. doi: 10.2147/DDDT.S308377
[36]	Jang JW, Kim MK, Bae SC. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the small GTPase pathway[J]. Small GTPases, 2020, 11(4): 280-288. DOI: 10.1080/21541248.2018.1435986. doi: 10.1080/21541248.2018.1435986